Identification

Summary

Sodium iodide is a supplement used in total parenteral nutrition.

Brand Names
Sclerodine
Generic Name
Sodium iodide
DrugBank Accession Number
DB11119
Background

Sodium iodide is a water-soluble ionic compound with a crystal lattice. Sodium iodide is a source of iodine and can be administered as a supplement for total parenteral nutrition 2 but is more commonly used in veterinary medicine. Radiolabelled compound, Iodide I-131, is used as a diagnostic tool to evaluate thyroid function and morphology.

Type
Small Molecule
Groups
Approved
Structure
Thumb
Weight
Average: 149.8942
Monoisotopic: 149.89424
Chemical Formula
INa
Synonyms
  • Sodium iodide

Pharmacology

Indication

Indicated for use as a supplement to intravenous solutions given for total parenteral nutrition (TPN) 2.

Pharmacology
Reduce drug development failure rates
Build, train, & validate machine-learning models
with evidence-based and structured datasets.
See how
Build, train, & validate predictive machine-learning models with structured datasets.
See how
Associated Conditions
Associated Therapies
Contraindications & Blackbox Warnings
Contraindications
Avoid life-threatening adverse drug events
Improve clinical decision support with information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.
Learn more
Avoid life-threatening adverse drug events & improve clinical decision support.
Learn more
Pharmacodynamics

When intravenously administered for total parental nutrition, sodium iodide prevents the depletion of endogenous stores of iodine and subsequent deficiency symptoms 2.

Mechanism of action
Not Available
Absorption

Iodide salts are readily absorbed in the gastrointestinal tract 1.

Volume of distribution

Iodides are distributed widely throughout extracellular fluid of thyroid gland 1.

Protein binding

Not Available

Metabolism
Not Available
Route of elimination

Iodides are expected to be renal excreted 1.

Half-life

Not Available

Clearance

Not Available

Adverse Effects
Adverseeffects
Improve decision support & research outcomes
With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates.
Learn more
Improve decision support & research outcomes with our structured adverse effects data.
Learn more
Toxicity

Acute oral LD50 is 4340 mg/kg in rat and 1000 mg/kg in mouse MSDS. Chronic iodide overdoses may result in iodism, which is commonly characterized by salivation, coryza, sneezing, conjunctivitis, headache, fever, laryngitis, bronchitis, stomatitis, parotitis and oedema of the glottis 1. Up to 10g of sodium iodide has been administered intravenously without any signs of toxicity 1.

Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Not Available
Food Interactions
No interactions found.

Products

Products2
Drug product information from 10+ global regions
Our datasets provide approved product information including:
dosage, form, labeller, route of administration, and marketing period.
Access now
Access drug product information from over 10 global regions.
Access now
Active Moieties
NameKindUNIICASInChI Key
Iodideionic09G4I6V86Q20461-54-5XMBWDFGMSWQBCA-UHFFFAOYSA-M
Sodium cationionicLYR4M0NH3717341-25-2FKNQFGJONOIPTF-UHFFFAOYSA-N
Brand Name Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing EndRegionImage
Iodopen Sodium IodideInjection, solution118 ug/1mLIntravenousFresenius Kabi USA, LLC2001-07-182015-09-30US flag
Micro ILiquid100 mcg / mLIntravenousSandoz Canada Incorporated1993-12-31Not applicableCanada flag
Sodium Iodide Inj 100mg/mlLiquid100 mg / mLIntravenousSabex Inc1988-12-311999-08-12Canada flag
Mixture Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing EndRegionImage
CVS IodineSodium iodide (20.4 mg/1mL) + Ethanol (470 mg/1mL) + Iodine (20 mg/1mL)LiquidTopicalCVS PHARMACY2008-01-01Not applicableUS flag
DDM Iodine Tincture MildSodium iodide (20.4 mg/1mL) + Ethanol (470 mg/1mL) + Iodine (20 mg/1mL)LiquidTopicalDiscount Drug Mart1979-01-01Not applicableUS flag
De La Cruz Tincture of IodineSodium iodide (20.4 mg/1mL) + Ethanol (470 mg/1mL) + Iodine (20 mg/1mL)LiquidTopicalDLC Laboratories, Inc.1979-01-01Not applicableUS flag
GNP Idoinde Tincture 2% MildSodium iodide (20.4 mg/1mL) + Ethanol (470 mg/1mL) + Iodine (20 mg/1mL)LiquidTopicalAmerisource Bergen2008-01-01Not applicableUS flag
Harris Teeter Iodine Tincture MildSodium iodide (20.4 mg/1mL) + Ethanol (470 mg/1mL) + Iodine (20 mg/1mL)LiquidTopicalHarris Teeter, LLC1979-01-01Not applicableUS flag
Health Mart Iodine Tincture MildSodium iodide (20.4 mg/1mL) + Ethanol (470 mg/1mL) + Iodine (20 mg/1mL)LiquidTopicalStrategic Sourcing Services LLC2011-01-01Not applicableUS flag
IodineSodium iodide (20.4 mg/1mL) + Ethanol (470 mg/1mL) + Iodine (20 mg/1mL)LiquidTopicalUNFI2005-02-04Not applicableUS flag
IodineSodium iodide (20.4 mg/1mL) + Ethanol (470 mg/1mL) + Iodine (20 mg/1mL)LiquidTopicalWalgreen Co2011-03-11Not applicableUS flag
IodineSodium iodide (20.4 mg/1mL) + Ethanol (470 mg/1mL) + Iodine (20 mg/1mL)LiquidTopicalVi-Jon, LLC2017-08-07Not applicableUS flag
IodineSodium iodide (20.4 mg/1mL) + Ethanol (470 mg/1mL) + Iodine (20 mg/1mL)LiquidTopicalVi-Jon, LLC2008-11-08Not applicableUS flag
Unapproved/Other Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing EndRegionImage
Iodopen Sodium IodideSodium iodide (118 ug/1mL)Injection, solutionIntravenousFresenius Kabi USA, LLC2001-07-182015-09-30US flag

Categories

Drug Categories
Chemical TaxonomyProvided by Classyfire
Description
This compound belongs to the class of inorganic compounds known as alkali metal iodides. These are inorganic compounds in which the largest halogen atom is Iodine, and the heaviest metal atom is an alkali metal.
Kingdom
Inorganic compounds
Super Class
Mixed metal/non-metal compounds
Class
Alkali metal salts
Sub Class
Alkali metal iodides
Direct Parent
Alkali metal iodides
Alternative Parents
Inorganic sodium salts
Substituents
Alkali metal iodide / Inorganic salt / Inorganic sodium salt
Molecular Framework
Not Available
External Descriptors
inorganic sodium salt, iodide salt (CHEBI:33167)
Affected organisms
Not Available

Chemical Identifiers

UNII
F5WR8N145C
CAS number
7681-82-5
InChI Key
FVAUCKIRQBBSSJ-UHFFFAOYSA-M
InChI
InChI=1S/HI.Na/h1H;/q;+1/p-1
IUPAC Name
sodium iodide
SMILES
[Na+].[I-]

References

General References
  1. SODIUM IODIDE - National Library of Medicine HSDB Database - Toxnet [Link]
  2. Dailymed - IODOPEN SODIUM IODIDE- sodium iodide injection, solution [Link]
KEGG Compound
C14042
PubChem Compound
5238
PubChem Substance
347827903
ChemSpider
5048
BindingDB
50098561
RxNav
9884
ChEBI
33167
ChEMBL
CHEMBL1644695
Wikipedia
Sodium_iodide
MSDS
Download (47.4 KB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
4CompletedPreventionTransient Hypothyroxinemia1
2RecruitingTreatmentFallopian Tube Carcinosarcoma / Fallopian Tube Clear Cell Adenocarcinoma / Fallopian Tube Endometrioid Adenocarcinoma / Fallopian Tube Mucinous Adenocarcinoma / Fallopian Tube Serous Adenocarcinoma / Fallopian Tube Transitional Cell Carcinoma / Ovarian Carcinosarcoma / Ovarian Clear Cell Adenocarcinoma / Ovarian Endometrioid Adenocarcinoma / Ovarian Mucinous Adenocarcinoma / Ovarian Seromucinous Carcinoma / Ovarian Serous Adenocarcinoma / Ovarian Transitional Cell Carcinoma / Platinum-Resistant Fallopian Tube Carcinoma / Platinum-Resistant Ovarian Carcinoma / Platinum-Resistant Primary Peritoneal Carcinoma / Primary Peritoneal Carcinosarcoma / Primary Peritoneal Clear Cell Adenocarcinoma / Primary Peritoneal Endometrioid Adenocarcinoma / Primary Peritoneal Serous Adenocarcinoma / Primary Peritoneal Transitional Cell Carcinoma / Primary Peritoneal Undifferentiated Carcinoma / Recurrent Fallopian Tube Carcinoma / Recurrent Ovarian Carcinoma / Recurrent Primary Peritoneal Carcinoma / Undifferentiated Fallopian Tube Carcinoma / Undifferentiated Ovarian Carcinoma1
1Active Not RecruitingTreatmentCarcinoma Breast Stage IV / Estrogen Receptor Negative / Estrogen Receptor Positive / HER2-positive / HER2/Neu Negative / Invasive Breast Carcinoma / Progesterone Receptor Negative / Progesterone Receptor Positive / Recurrent Head and Neck Carcinoma / Squamous Cell Carcinoma Head and Neck Cancer (HNSCC) / Triple Negative Breast Carcinoma1
1CompletedTreatmentOvarian Cancer / Primary Peritoneal Cavity Cancer1
1CompletedTreatmentRecurrent Malignant Mesothelioma / Stage IA Malignant Mesothelioma / Stage IB Malignant Mesothelioma / Stage II Malignant Mesothelioma / Stage III Malignant Mesothelioma / Stage IV Malignant Mesothelioma1
1RecruitingTreatmentMetastatic Endometrial carcinoma / Recurrent Endometrial Adenocarcinoma / Recurrent Endometrial Carcinoma / Recurrent Endometrial Clear Cell Adenocarcinoma / Recurrent Endometrial Endometrioid Adenocarcinoma / Recurrent Endometrial Mixed Cell Adenocarcinoma / Recurrent Endometrial Serous Adenocarcinoma / Recurrent Endometrial Undifferentiated Carcinoma / Recurrent Uterine Corpus Carcinosarcoma / Stage IV Uterine Corpus Cancer AJCC v7 / Stage IVA Uterine Corpus Cancer AJCC v7 / Stage IVB Uterine Corpus Cancer AJCC v71
1RecruitingTreatmentMetastatic Malignant Peripheral Nerve Sheath Tumor / Neurofibromatosis Type 1 (NF1) / Recurrent Malignant Peripheral Nerve Sheath Tumor1
1RecruitingTreatmentMyelodysplastic Syndromes (MDS) / Myelodysplastic Syndromes, Previously Treated / Recurrent Acute Myeloid Leukemia, Adult / Recurrent Anaplastic Large Cell Lymphoma / Recurrent Angioimmunoblastic T-cell Lymphoma / Recurrent Mycosis Fungoides / Recurrent Plasma Cell Myeloma / Recurrent Primary Cutaneous T-Cell Non-Hodgkin Lymphoma / Recurrent T-Cell Non-Hodgkin Lymphoma / Refractory Acute Myelogenous Leukemia (AML) / Refractory Anaplastic Large Cell Lymphoma / Refractory Angioimmunoblastic T-cell Lymphoma / Refractory Peripheral T-Cell Lymphoma, Not Otherwise Specified / Refractory Plasma Cell Myeloma / Refractory T-Cell Non-Hodgkin Lymphoma / Refractory, advanced Mycosis fungoides / Refractory, primary Cutaneous T-Cell Non-Hodgkin Lymphoma1
1, 2CompletedTreatmentRecurrent Plasma Cell Myeloma / Refractory Plasma Cell Myeloma1
1, 2RecruitingTreatmentFallopian Tube Clear Cell Adenocarcinoma / Fallopian Tube Endometrioid Adenocarcinoma / Fallopian Tube Mucinous Adenocarcinoma / Fallopian Tube Serous Adenocarcinoma / Fallopian Tube Transitional Cell Carcinoma / Malignant Ovarian Brenner Tumor / Ovarian Clear Cell Adenocarcinoma / Ovarian Endometrioid Adenocarcinoma / Ovarian Mucinous Adenocarcinoma / Ovarian Seromucinous Carcinoma / Ovarian Serous Adenocarcinoma / Ovarian Transitional Cell Carcinoma / Primary Peritoneal Serous Adenocarcinoma / Recurrent Fallopian Tube Carcinoma / Recurrent Ovarian Carcinoma / Recurrent Primary Peritoneal Carcinoma / Undifferentiated Fallopian Tube Carcinoma / Undifferentiated Ovarian Carcinoma1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
FormRouteStrength
SolutionTopical
Solution / dropsTopical
SprayTopical
TinctureTopical
Injection, solutionIntravenous118 ug/1mL
LiquidIntravenous100 mcg / mL
SolutionIntravenous
Capsule, coatedOral7400 MBq
TabletOral
LiquidTopical
LiquidIntravenous
LiquidIntravenous100 mg / mL
Injection, solutionIntravenous
Capsule, coatedOral37 MBq
Solution / dropsOphthalmic
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
PropertyValueSource
melting point (°C)651MSDS
boiling point (°C)DecomposesMSDS
water solubilitySolubleMSDS
Predicted Properties
PropertyValueSource
logP1.02ChemAxon
pKa (Strongest Acidic)-9ChemAxon
Physiological Charge-1ChemAxon
Hydrogen Acceptor Count0ChemAxon
Hydrogen Donor Count0ChemAxon
Polar Surface Area0 Å2ChemAxon
Rotatable Bond Count0ChemAxon
Refractivity13.95 m3·mol-1ChemAxon
Polarizability5.07 Å3ChemAxon
Number of Rings0ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterNoChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET Features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
Not Available

Drug created at December 03, 2015 16:51 / Updated at December 04, 2021 10:27